<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Poliovirus vaccination</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Poliovirus vaccination</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Poliovirus vaccination</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Modlin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Immunization against poliovirus infection represents one of the world's great medical achievements. The last cases of naturally occurring wild type paralytic poliomyelitis in the United States occurred during a small outbreak due to type 1 poliovirus in an unvaccinated religious community in 1978 to 1979 [<a href="#rid1">1</a>]. </p><p>As of January 2024, wild type 1 poliovirus (WPV1) remains endemic only in Pakistan and Afghanistan. Outbreaks caused by circulating oral polio vaccine-derived (cVDPV) type 2 strains now extend through much of sub-Saharan Africa, Pakistan, and Afghanistan, and in 2022 these strains were reported in certain localities of the United States, United Kingdom, and Israel [<a href="#rid2">2-5</a>].</p><p>Issues related to paralytic poliomyelitis, the post-polio syndrome, and global eradication of poliomyelitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/97003.html" rel="external">"Global poliomyelitis eradication"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">POLIOVIRUS VACCINES</span><span class="headingEndMark"> — </span>Both inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (IPV) and live attenuated oral poliovirus vaccine (OPV) were developed in the 1950s and have since been used worldwide for routine childhood immunization and to prevent and control polio outbreaks in endemic countries [<a href="#rid6">6-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Since 2000, IPV is the only <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> available for routine infant and childhood immunization in the United States [<a href="#rid9">9</a>]. It is the preferred vaccine in most middle- and upper-income countries because it is safe, highly effective, incapable of causing vaccine-associated poliomyelitis (VAPP) and can be combined with other vaccines given by intramuscular injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A combination of type 1 and 3 bivalent OPV (bOPV) vaccine and IPV is recommended by the World Health Organization (WHO) Expanded Program on Immunization (EPI) for routine infant immunization in low-income countries. In this context, IPV provides protection against disease caused by type 2 polioviruses and a boost in immunity to types 1 and 3. OPV vaccines are used for supplementary immunization activities in countries at increased risk of poliovirus transmission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monovalent OPV vaccines for types 1, 2, and 3 (mOPV1, mOPV2, and mOPV3, respectively) are stockpiled by the Global Polio Eradication Initiative and deployed selectively in response to polio outbreaks [<a href="#rid10">10</a>]. A novel type 2 oral polio vaccine (nOPV2) was authorized for emergency use in countries at risk of circulating vaccine-derived poliovirus (cVDPV) type 2 transmission in November 2020, as further discussed below [<a href="#rid11">11,12</a>]. (See <a class="local">'Monovalent OPV vaccines and nOPV2'</a> below.)</p><p></p><p>Worldwide polio immunization practice has initiated a phased transition from OPV to IPV in anticipation of global polio eradication in the future, beginning with cessation of type 2 OPV use in April 2016 and the addition of IPV to the EPI schedule [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/97003.html" rel="external">"Global poliomyelitis eradication"</a> and <a class="local">'Recommendations of the WHO'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Inactivated poliovirus vaccine</span><span class="headingEndMark"> — </span>IPV is prepared by inactivation of wild type or Sabin (OPV) strain polioviruses by treatment with dilute formalin [<a href="#rid14">14-16</a>]. IPV is combined with other infant vaccines including diphtheria-tetanus-acellular pertussis, hepatitis B vaccine, and <em>Haemophilus influenzae</em> type B vaccine in multivalent formulations for intramuscular administration in most upper- and middle-income countries. Standalone IPV vaccines are now included in infant immunization schedules in low-income countries that have replaced trivalent OPV (tOPV) with bOPV.</p><p class="headingAnchor" id="H4"><span class="h3">Immune response and efficacy</span><span class="headingEndMark"> — </span>IPV seroconversion rates and antibody titers depend on the number of doses, the interval between doses, age at the first dose, and maternal antibody levels. In general, three doses administered at 2, 4, and 6 to 18 months of age are expected to induce seroconversion in &gt;95 percent of infants [<a href="#rid17">17,18</a>]. A 6-, 10-, and 14-week schedule results in lower but effective seroconversion rates [<a href="#rid18">18</a>].</p><p>Detectable antibody persists at protective levels for at least five years, although geometric mean titers decline. In some cases, the level of antibody may fall below detectable levels over time, but persons who have previously seroconverted are likely protected by immune memory.</p><p>Fractional doses (equal to 0.2 times a full dose, delivered by intradermal or intramuscular injection) that mitigate the high cost of IPV have been adopted by India, Bangladesh, Sri Lanka, and Nepal. Dose per dose, fractional doses result in lower seroconversion rates than full doses but effectively boost pre-existing antibody titers [<a href="#rid19">19-21</a>].</p><p>The influence of primary IPV immunization on mucosal immunity is quite limited compared with OPV. However, IPV boosts both humoral and intestinal immunity in children who have previously received OPV [<a href="#rid22">22</a>]. In a trial including children in Sri Lanka (previously vaccinated with OPV) who received booster vaccination with a fractional dose of IPV or a full dose of IPV (administered intradermally), mucosal immunity was boosted to a similar extent in each group [<a href="#rid23">23</a>].</p><p>There have been few opportunities to assess the efficacy of current IPV vaccine formulations under conditions of natural exposure to wild type or cVDPV. A case-control study conducted following a type 1 poliomyelitis outbreak in Senegal in 1986 to 1987 found that one and two IPV doses administered to children provided 36 percent (CI 0 to 67 percent) and 89 percent (CI 62 to 97 percent) efficacy, respectively, against paralytic disease, albeit with wide confidence intervals [<a href="#rid24">24</a>]. Similarly, a study in Tamil Nadu, India, found that three IPV doses had an efficacy of 92 percent [<a href="#rid25">25</a>]. These efficacy estimates track observed seroconversion rates for one and two IPV doses, respectively [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Transient local reactions (erythema, pain, induration) are comparable with reactions following a placebo injection [<a href="#rid17">17</a>]. With the exception of a single incident in which inadequately inactivated IPV from one manufacturer caused a serious outbreak of poliomyelitis shortly after initial licensure in the 1950s [<a href="#rid27">27</a>], there are no proven serious adverse events associated with IPV.</p><p class="headingAnchor" id="H6"><span class="h2">Live attenuated oral poliovirus vaccine</span><span class="headingEndMark"> — </span>OPVs were developed by repeated passage of wild type polioviruses in primates and in cell culture [<a href="#rid7">7</a>].</p><p>OPV remains an important tool for control of poliovirus transmission in the developing world because of low cost, ease of administration, induction of mucosal immunity, and enhancement of household and population immunity by transmission of OPV viruses from OPV-vaccinated children to their nonimmune contacts [<a href="#rid28">28</a>]. A trivalent OPV formulation (tOPV) containing Sabin 1, 2, and 3 vaccine viruses was used worldwide until April 2016 when it was replaced with bivalent type 1 and type 3 OPV during a global synchronized switch [<a href="#rid29">29</a>]. Withdrawal of type 2 OPV was considered essential because type 2 wild polioviruses no longer circulate, and continued use of Sabin 2 viruses has been responsible for a disproportionate number of vaccine-associated paralytic poliomyelitis (VAPP) and circulating vaccine-derived poliovirus (cVDPV) cases [<a href="#rid30">30</a>]. Despite continued challenges, the strategic plan of the Global Polio Eradication Program calls for all OPV vaccination to cease and be replaced with IPV once all poliovirus transmission has been interrupted [<a href="#rid31">31</a>].</p><p>OPV vaccines are no longer licensed in the United States.</p><p>An optimal immune response to OPV requires multiple doses. When previously used in high- and middle-income countries, three tOPV doses given at least two months apart induced ≥96 percent seroconversion to all three types after the third dose [<a href="#rid17">17</a>], and detectable serum antibody to all three types persisted in 84 to 98 percent of vaccinees five years after primary immunization [<a href="#rid32">32</a>]. However, in some low-income countries, a series of tOPV doses at birth and at 6, 10, and 14 weeks of age induced lower seroconversion rates [<a href="#rid33">33-37</a>], averaging 73, 90, and 70 percent for types 1, 2, and 3, respectively [<a href="#rid29">29</a>]. </p><p>Diarrheal disease and other enteropathies associated with poor sanitation inhibit replication of OPV vaccine viruses in the gastrointestinal tract and thereby limit the immune response. One study conducted in Brazil and the Gambia [<a href="#rid29">29,38</a>] and another one conducted in Bangladesh [<a href="#rid39">39</a>] showed that diarrhea reduced seroconversion rates to types 2 and 3 OPV, while the response to type 1 was not affected. The impact of diarrhea on seroconversion persists despite the administration of three or four trivalent OPV doses.</p><p class="headingAnchor" id="H8"><span class="h3">Bivalent type 1 and type 3 OPV</span><span class="headingEndMark"> — </span>Bivalent type 1 and type 3 OPV vaccine (bOPV) is the only OPV routinely used for infant immunization worldwide. The absence of interference from type 2 poliovirus in the trivalent formulation leads to superior bOPV immunogenicity for types 1 and 3 compared with tOPV [<a href="#rid40">40</a>].</p><p>An optimal immune response to bOPV requires multiple doses. Trials in Latin America and Bangladesh have demonstrated seroconversion rates of &gt;94 percent to both type 1 and type 3 OPV among infants vaccinated with three bOPV doses at 6, 10, and 14 weeks of age [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H2153480250"><span class="h3">Monovalent OPV vaccines and nOPV2</span><span class="headingEndMark"> — </span>Monovalent OPV vaccines for types 1, 2, and 3 (mOPV1, mOPV2, and mOPV3, respectively) are stockpiled by the Global Polio Eradication Initiative and deployed selectively in response to polio outbreaks [<a href="#rid10">10</a>].</p><p>A novel genetically stable type 2 OPV vaccine (nOPV2) has been created to address the ongoing risk of reversion of mOPV2 viruses to a virulent phenotype when deployed in response to cVDPV2 outbreaks. Clinical nOPV2 trials confirmed seroprotection and safety profiles comparable to mOPV2 [<a href="#rid11">11,12,43</a>]. Based on these studies, in 2020 the WHO authorized the emergency use of nOPV2 in all ages, including infants. Since then, 800 million doses have been administered in 23 countries [<a href="#rid9">9,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/97003.html" rel="external">"Global poliomyelitis eradication"</a>.)</p><p class="headingAnchor" id="H2012332074"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of OPV was never tested under conditions of exposure to natural polioviruses in the United States; however, nearly four decades of use from 1961 to 2000 provided overwhelming evidence of OPV effectiveness. OPV efficacy was directly evaluated during a type 1 poliovirus outbreak in Taiwan in the early 1980s when vaccine efficacy was estimated to be 82, 96, and 98 percent for one, two, and three or more doses, respectively [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>OPV viruses are shed from the oropharynx for up to 7 to 14 days after administration and in the stool for as long as 6 to 8 weeks in normal infants [<a href="#rid46">46</a>]. Stool shedding is accompanied by rapid loss of attenuating mutations in each of the three serotypes and an increase in phenotypic neurovirulence markers [<a href="#rid47">47</a>].</p><p>VAPP is a rare but important consequence of reversion to neurovirulence, which was reported in an average of nine persons per year in the United States between 1961 and 1997 [<a href="#rid48">48,49</a>] and which was estimated to occur in 3.8 persons per million births or 399 cases (range 306 to 490) in tOPV-using countries [<a href="#rid50">50</a>]. The removal of OPV2 from the vaccine in 2016 is has since reduced the incidence by approximately 60 percent. VAPP occurs in OPV recipients (mostly infants) and in direct contacts of OPV recipients (mostly adult caretakers with inadequate immunity). The overall risk is about 1 case per 900,000 first-dose OPV recipients [<a href="#rid51">51</a>]. Subsequent doses are less likely to be associated with VAPP in the United States but carry a higher risk in resource-poor countries, where OPV viruses may be less likely to replicate in the gastrointestinal tract following the first OPV dose [<a href="#rid50">50</a>]. Individuals with B cell immunodeficiency carry the highest risk, with an estimated VAPP rate of 2 per 1000 vaccinees [<a href="#rid52">52,53</a>]. For this reason, OPV is contraindicated for immunodeficient individuals.</p><p>In settings with inadequate vaccine coverage, OPV viruses can spread into the community as cVDPV that accumulate neurovirulent traits indistinguishable from wild type polioviruses through loss of attenuating mutations created in OPV. The emergence of cVDPV has fundamentally influenced plans for the eventual cessation of poliovirus immunization following eradication of poliomyelitis, which will include a strategy to discontinue OPV use, introduce IPV for risk mitigation, develop monovalent OPV vaccine stockpiles to deploy for cVDPV outbreaks like those occurring in Africa [<a href="#rid2">2</a>], and plan for containment of laboratory stocks of naturally occurring and attenuated polioviruses [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/z/d/html/97003.html" rel="external">"Global poliomyelitis eradication"</a>.)</p><p>Other than VAPP, there are no adverse reactions attributed to OPV. The available data suggest that OPV does not increase the risk of fetal malformation or other adverse pregnancy outcomes [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H6529745"><span class="h1">RECOMMENDATIONS OF THE WHO</span><span class="headingEndMark"> — </span>Most countries that adopt the World Health Organization (WHO) Expanded Program on Immunization (EPI) schedule for routine infant immunization administer bivalent oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> at birth and at 6, 10, and 14 weeks of age and two doses of inactivated poliovirus vaccine (IPV) at ≥14 weeks and 9 months of age to boost immunity to poliovirus types 1 and 3 and to provide protection against poliovirus type 2 [<a href="#rid58">58</a>]. This regimen induces seroconversion to all three types in &gt;90 percent of infants by 12 months of age [<a href="#rid59">59-61</a>].</p><p>For countries that employ IPV alone, the WHO recommends three doses for countries that use a 2, 4, and 6 month schedule for routine infant immunization and four doses for countries that use a 6, 10, 14 week schedule; the fourth dose should be administered ≥6 months after the third dose.</p><p>For countries that have introduced sequential IPV-oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (OPV) schedules, one or two IPV doses followed by a minimum of two OPV doses are recommended.</p><p class="headingAnchor" id="H10"><span class="h1">RECOMMENDATIONS OF THE CDC</span><span class="headingEndMark"> — </span>Inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (IPV) is the only vaccine recommended by the United States Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices and the American Academy of Pediatrics for routine immunization in the United States [<a href="#rid62">62-64</a>]. Oral poliovirus vaccine (OPV) is no longer licensed in the United States. Licensed vaccines containing IPV are summarized in the table  (<a class="graphic graphic_table graphicRef78224" href="/z/d/graphic/78224.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H11"><span class="h2">Infants and children</span><span class="headingEndMark"> — </span>The recommended polio vaccination series in the United States consists of four doses of IPV administered subcutaneously or intramuscularly [<a href="#rid63">63</a>]. The first and second doses are administered at 2 and 4 months of age, respectively. The third dose may be given at 6 to 18 months of age, and a fourth dose is given at 4 to 6 years of age before school entry [<a href="#rid64">64</a>]. The minimum interval between doses 1 and 2 and between doses 2 and 3 is four weeks, and the minimum interval between doses 3 and 4 is six months. The minimum age for dose 1 is six weeks. Minimum age and intervals should be applied when there is imminent threat of exposure, such as travel to an area in which polio is endemic or epidemic. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Routine schedule'</a>.)</p><p>Children who are inadequately vaccinated should complete the vaccination series. The fourth dose is not required if the third dose of IPV was delayed until after the child's fourth birthday.</p><p class="headingAnchor" id="H12"><span class="h2">Adults</span><span class="headingEndMark"> — </span>Polio vaccination is recommended for all adults known or suspected to be unvaccinated or incompletely vaccinated against polio [<a href="#rid65">65</a>]. </p><p>In addition, polio vaccination is recommended for individuals at increased risk for exposure; this includes [<a href="#rid66">66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Travelers to areas or countries when polio is endemic or epidemic (see  <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Poliovirus vaccine'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Members of communities or population groups with disease caused by wild polioviruses</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unvaccinated adults whose children will receive OPV</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Health care workers who have close contact with patients who might be excreting wild polioviruses or laboratory workers who handle specimens that may contain polioviruses</p><p></p><p>Adults at increased risk who have had a primary vaccination series with IPV or OPV should receive a single booster dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose of IPV. An exception are adults who will be in a polio-exporting or polio-infected country for &gt;4 weeks and received a booster dose &gt;12 months earlier; they should receive an additional dose of IPV or OPV before exiting that country [<a href="#rid67">67</a>]. (See <a class="local">'Recommendations for travelers'</a> below.)</p><p>Adults at increased risk who are unvaccinated or whose vaccination status is not documented should receive a primary vaccination series with IPV. This consists of two doses of IPV at 4- to 8-week intervals and a third dose 6 to 12 months after the second dose. If this regimen cannot be completed within the recommended intervals before protection is needed, the following alternatives are recommended:</p><p class="bulletIndent1"><span class="glyph">●</span>If there are more than eight weeks before protection is needed, three doses of IPV should be given at least four weeks apart.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there are only four to eight weeks before protection is needed, two doses of IPV should be given at least four weeks apart.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there are less than four weeks before protection is needed, a single dose of IPV should be given.</p><p></p><p>For the second and third options, the remaining doses should be given later at the recommended intervals if the person remains at risk for exposure to poliovirus.</p><p class="headingAnchor" id="H13"><span class="h2">Pregnant women</span><span class="headingEndMark"> — </span>Although adverse effects of IPV have not been documented in either the mother or the fetus, vaccination is not recommended during pregnancy on theoretical grounds [<a href="#rid64">64,66</a>]. If, however, a pregnant woman is at increased risk for infection and requires immediate protection, IPV should be given according to the above schedule in adults. (See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Poliovirus'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Immunocompromised patients</span><span class="headingEndMark"> — </span>IPV is the only vaccine recommended for immunodeficient individuals and their household contacts [<a href="#rid68">68</a>]. However, a protective immune response cannot be assured in patients who are immunodeficient at the time of vaccination. The response in hematopoietic cell transplant recipients is optimized when more than one dose is administered at least 12 months after transplantation [<a href="#rid69">69-71</a>]. (See  <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Poliovirus vaccine'</a>.)</p><p class="headingAnchor" id="H613228191"><span class="h2">Recommendations for travelers</span><span class="headingEndMark"> — </span>The CDC recommends that travelers to poliovirus-affected areas be fully vaccinated against poliovirus with the age-appropriate vaccine series; adults should also receive a one-time booster dose of a <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> [<a href="#rid72">72,73</a>]. Information about recent cases can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpolioeradication.org%2Fwho-we-are%2F&amp;token=nuxP6qxgqkJaAv4bVh4PhmtEyaYkEgiswRmTQhxJYkjfrISio59C8gOPnxeWly%2F2rwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=2695" target="_blank">Global Polio Eradication Initiative website</a>. Detailed recommendations regarding vaccination can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fyellowbook%2F2020%2Ftravel-related-infectious-diseases%2Fpoliomyelitis&amp;token=wWby1Gr%2Bvqa89m7E%2BdnqIcQKsl9feoscwvDT8ssVhYeCSTqpHUiFJ4dzyBV1VJEnBLEAVhNhOdzr87Sj2NXRjrfdvGWJizbXEEonxhsVmceHlLs5gzOZgKkX2DEFzRXb&amp;TOPIC_ID=2695" target="_blank">CDC website</a>.</p><p>In 2014, the international spread of wild poliovirus was declared by the World Health Organization to be a Public Health Emergency of International Concern. Temporary recommendations to reduce the international spread of wild poliovirus were issued, and the situation has been reassessed at three-month intervals thereafter. The country-specific temporary recommendations issued in August 2023 are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fnews-room%2Fdetail%2F08-04-2020-statement-of-the-twenty-fourth-ihr-emergency-committee&amp;token=un7RN83axBVJoJvNs%2Binb%2BvagDjGxR%2BSTmZiR99r8O4Dw2LJb24NJ4vzPGck2nmXiJ7Suzeq6UcMIjKCxHgUH8sFu4rUw3zzizjzhm%2B7qKUiItZyO7x10fKuc10Nm6OB&amp;TOPIC_ID=2695" target="_blank">International Health Regulations Emergency committee</a> [<a href="#rid74">74,75</a>].</p><p>The burden for implementation and enforcement of these recommendations lies with the poliovirus-affected countries. For countries that implement this recommendation, previous vaccination history is to be disregarded, and the required dose must have been given within the previous 12 months. Travel health practitioners should be aware of these individual country exit requirements in order to discuss whether vaccination prior to travel to the listed countries might be advisable. Travelers who are vaccinated should be provided with an International Certificate of Vaccination or Prophylaxis to serve as proof of vaccination.</p><p>Poliovirus immunization for travel is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Poliovirus vaccine'</a>.)</p><p class="headingAnchor" id="H2373566155"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110427.html" rel="external">"Society guideline links: Immunizations in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/134422.html" rel="external">"Society guideline links: Polio"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83751.html" rel="external">"Patient education: Poliomyelitis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1214.html" rel="external">"Patient education: Why does my child need vaccines? (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10008932"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine schedule</strong> – Inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (IPV) is the preferred vaccine for developed countries because it does not cause vaccine-associated paralytic poliomyelitis (VAPP) and can be combined with other routine childhood vaccines. The polio vaccination series in the United States consists of four doses of IPV administered at 2 months, 4 months, 6 to 18 months, and 4 to 6 years of age. (See <a class="local">'Inactivated poliovirus vaccine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred vaccine formulation</strong> – Bivalent oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (bOPV) is the preferred vaccine for routine infant immunization in countries at increased risk of poliovirus transmission. Advantages to the use of bOPV include cost, ease of administration, and low risk of transmission of vaccine virus to unimmunized contacts. The WHO recommends a bivalent OPV dose at birth, followed by a primary series of three OPV doses (at 6, 10, and 14 weeks) as well as two IPV doses (at ≥14 weeks and 9 months of age). (See <a class="local">'Live attenuated oral poliovirus vaccine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine-derived polioviruses (VDPVs)</strong> – VDPVs are Sabin (OPV) virus derivatives that circulate in settings of low population immunity (eg, with low immunization rates) and revert to neurovirulence with ongoing transmission. The emergence of VDPV requires that use of all OPV vaccines must cease to achieve the goal of global poliomyelitis eradication. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine-associated paralytic poliomyelitis (VAPP)</strong> – VAPP occurs as a result of reversion of an attenuated viral strain to a neurovirulent strain. OPV has been associated with rare cases of VAPP in vaccine recipients and their contacts. (See <a class="local">'Adverse effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kim-Farley RJ, Bart KJ, Schonberger LB, et al. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus. Lancet 1984; 2:1315.</a></li><li><a class="nounderline abstract_t">Macklin G, Liao Y, Takane M, et al. Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry. Front Immunol 2017; 8:1103.</a></li><li><a class="nounderline abstract_t">Klapsa D, Wilton T, Zealand A, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet 2022; 400:1531.</a></li><li><a class="nounderline abstract_t">Zuckerman NS, Bar-Or I, Sofer D, et al. Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill 2022; 27.</a></li><li><a class="nounderline abstract_t">Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1065.</a></li><li class="breakAll">Francis T, Napier JA, Voight RB, et al. Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine. Final Report. Vaccine Evaluation Center, Department of Epidemiology, University of Michigan, Ann Arbor, MI 1957.</li><li><a class="nounderline abstract_t">Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151:420.</a></li><li><a class="nounderline abstract_t">SALK JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 1953; 151:1081.</a></li><li><a class="nounderline abstract_t">Nanque LM, Fisker AB. Maximising the lessons learned from trial data after emergency use listing of a novel oral polio vaccine. Lancet 2023; 401:83.</a></li><li><a class="nounderline abstract_t">Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001; 33:531.</a></li><li><a class="nounderline abstract_t">Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet 2021; 397:27.</a></li><li><a class="nounderline abstract_t">De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 2021; 397:39.</a></li><li class="breakAll">Poliomyelitis (polio). World Health Organization. https://www.who.int/health-topics/poliomyelitis#tab=tab_1 (Accessed on January 19, 2023).</li><li><a class="nounderline abstract_t">Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012; 205:237.</a></li><li><a class="nounderline abstract_t">Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997; 16:312.</a></li><li><a class="nounderline abstract_t">Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016; 34:1975.</a></li><li><a class="nounderline abstract_t">McBean AM, Thoms ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128:615.</a></li><li><a class="nounderline abstract_t">Estívariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013; 3:309.</a></li><li><a class="nounderline abstract_t">Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416.</a></li><li><a class="nounderline abstract_t">Estívariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012; 12:128.</a></li><li><a class="nounderline abstract_t">Snider CJ, Zaman K, Estivariz CF, et al. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet 2019; 393:2624.</a></li><li><a class="nounderline abstract_t">John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014; 384:1505.</a></li><li><a class="nounderline abstract_t">Gamage D, Mach O, Palihawadana P, et al. Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine. J Infect Dis 2018; 218:1876.</a></li><li><a class="nounderline abstract_t">Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 1:897.</a></li><li><a class="nounderline abstract_t">Kurstak E. World Conference on Poliomyelitis and Measles: Vaccines and Immunization. 7-12 January 1992, New Delhi, India. Vaccine 1993; 11:93.</a></li><li><a class="nounderline abstract_t">Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014; 210 Suppl 1:S439.</a></li><li><a class="nounderline abstract_t">NATHANSON N, LANGMUIR AD. THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. I. BACKGROUND. Am J Hyg 1963; 78:16.</a></li><li><a class="nounderline abstract_t">SABIN AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 1957; 164:1216.</a></li><li><a class="nounderline abstract_t">Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926.</a></li><li><a class="nounderline abstract_t">Garon J, Seib K, Orenstein WA, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines 2016; 15:693.</a></li><li><a class="nounderline abstract_t">Pallansch MA. Ending Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame. N Engl J Med 2018; 379:801.</a></li><li><a class="nounderline abstract_t">Krugman RD, Hardy GE Jr, Sellers C, et al. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics 1977; 60:80.</a></li><li><a class="nounderline abstract_t">John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972; 96:263.</a></li><li><a class="nounderline abstract_t">John TJ. Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. Am J Epidemiol 1975; 102:414.</a></li><li><a class="nounderline abstract_t">Dömök I, Balayan MS, Fayinka OA, et al. Factors affecting the efficacy of live poliovirus vaccine in warm climates. Efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda. Bull World Health Organ 1974; 51:333.</a></li><li><a class="nounderline abstract_t">de Brito Bastos NC, Carvalho Filho ES de+CARVALHOAAFILHO ES, Schatzmayr H, et al. Antipoliomyelitis program in Brazil; a erologic study of immunity levels. Bull Pan Am Health Organ 1974; 8:54.</a></li><li><a class="nounderline abstract_t">Lasch EE, Abed Y, Abdulla K, et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6 Suppl 2:S467.</a></li><li class="breakAll">WHO Collaborative Study Group on Oral Poliovirus Vaccine. Effect of diarrhea on seroconversion to oral poliovirus vaccine. In: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim CA 1992.</li><li><a class="nounderline abstract_t">Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996; 15:204.</a></li><li><a class="nounderline abstract_t">Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376:1682.</a></li><li><a class="nounderline abstract_t">Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine 2015; 33:6816.</a></li><li><a class="nounderline abstract_t">O'Ryan M, Bandyopadhyay AS, Villena R, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis 2015; 15:1273.</a></li><li><a class="nounderline abstract_t">Bandyopadhyay AS, Zipursky S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect Dis 2023; 23:e67.</a></li><li class="breakAll">cVDPV2 outbreaks and the type 2 novel oral polio vaccine (nOPV2). Polio Global Eradication Initiative. https://polioeradication.org/wp-content/uploads/2022/10/GPEI-nOPV2-Factsheet-EN-20221011.pdf (Accessed on January 19, 2023).</li><li><a class="nounderline abstract_t">Kim-Farley RJ, Rutherford G, Lichfield P, et al. Outbreak of paralytic poliomyelitis, Taiwan. Lancet 1984; 2:1322.</a></li><li><a class="nounderline abstract_t">Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997; 175 Suppl 1:S176.</a></li><li><a class="nounderline abstract_t">Macadam AJ, Stone DM, Almond JW, Minor PD. The 5' noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol 1994; 2:449.</a></li><li><a class="nounderline abstract_t">Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J Med Virol 2005; 75:153.</a></li><li><a class="nounderline abstract_t">DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011; 364:2316.</a></li><li><a class="nounderline abstract_t">Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014; 210 Suppl 1:S380.</a></li><li><a class="nounderline abstract_t">Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004; 292:1696.</a></li><li><a class="nounderline abstract_t">Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994; 11:426.</a></li><li><a class="nounderline abstract_t">Wyatt HV. Letter: Risk of live poliovirus in immunodeficient children. J Pediatr 1975; 87:152.</a></li><li><a class="nounderline abstract_t">Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587.</a></li><li><a class="nounderline abstract_t">Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. "Endgame" issues for the global polio eradication initiative. Clin Infect Dis 2002; 34:72.</a></li><li class="breakAll">World Health Organization Global Poliomyelitis Eradication Program. Global Eradication Initiative Strategic Plan, 2004-2008 http://www.polioeradication.org/content/publications/2004stratplan.pdf (Accessed on October 12, 2011).</li><li><a class="nounderline abstract_t">Harjulehto T, Aro T, Hovi T, Saxén L. Congenital malformations and oral poliovirus vaccination during pregnancy. Lancet 1989; 1:771.</a></li><li><a class="nounderline abstract_t">Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec 2016; 91:145.</a></li><li><a class="nounderline abstract_t">Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet 2016; 388:158.</a></li><li><a class="nounderline abstract_t">Sutter RW, Bahl S, Deshpande JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 2015; 386:2413.</a></li><li><a class="nounderline abstract_t">Saleem AF, Mach O, Yousafzai MT, et al. Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan. J Infect Dis 2018; 217:443.</a></li><li class="breakAll">Committee on Infectious Diseases. Report of the Committee on Infectious Diseases 2003.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep 2009; 58:829.</a></li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li><a class="nounderline abstract_t">Kidd S, Clark T, Routh J, et al. Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1327.</a></li><li><a class="nounderline abstract_t">Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.</a></li><li><a class="nounderline abstract_t">Wallace GS, Seward JF, Pallansch MA, Centers for Disease Control and Prevention. Interim CDC guidance for polio vaccination for travel to and from countries affected by wild poliovirus. MMWR Morb Mortal Wkly Rep 2014; 63:591.</a></li><li><a class="nounderline abstract_t">Ehrenfeld E, Chumakov K. Monovalent oral poliovirus vaccines--a good tool but not a total solution. N Engl J Med 2008; 359:1726.</a></li><li><a class="nounderline abstract_t">Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16.</a></li><li><a class="nounderline abstract_t">Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89.</a></li><li><a class="nounderline abstract_t">Pauksen K, Hammarström V, Ljungman P, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18:547.</a></li><li class="breakAll">Centers for Disease Control and Prevention. CDC Health Advisory. Guidance to US clinicians regarding new WHO polio vaccination requirements for travel by residents of and long-term visitors to countries with active polio transmission. http://emergency.cdc.gov/han/han00362.asp (Accessed on June 03, 2014).</li><li class="breakAll">Centers for Disease Control and Prevention. Chapter 3. Infections diseases related to travel: Poliomyelitis. http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/poliomyelitis (Accessed on June 03, 2014).</li><li class="breakAll">WHO statement on the meeting of the International Health Regulations Emergency Committee concerning the international spread of wild poliovirus. http://www.who.int/mediacentre/news/statements/2014/polio-20140505/en/ (Accessed on June 03, 2014).</li><li class="breakAll">World Health Organization. Statement of the Thirty-sixth Meeting of the Polio IHR Emergency Committee, 2023. https://www.who.int/news/item/25-08-2023-statement-of-the-thirty-sixth-meeting-of-the-polio-ihr-emergency-committee#:~:text=Conclusion,for%20a%20further%20three%20months. (Accessed on January 18, 2024).</li></ol></div><div id="topicVersionRevision">Topic 2695 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6150330" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Poliomyelitis in the USA: virtual elimination of disease caused by wild virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993765" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36243024" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36111556" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980868" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980868" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2982959" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13034436" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36495877" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Maximising the lessons learned from trial data after emergency use listing of a novel oral polio vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462191" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33308427" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33308429" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33308429" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158682" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076821" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25448090" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843039" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759252" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Poliovirus vaccination options for achieving eradication and securing the endgame.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23363495" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Priming after a fractional dose of inactivated poliovirus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071249" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31104832" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018120" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982532" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895828" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427041" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : World Conference on Poliomyelitis and Measles: Vaccines and Immunization. 7-12 January 1992, New Delhi, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24634499" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14043543" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. I. BACKGROUND.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13438685" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Properties and behavior of orally administered attenuated poliovirus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1660184" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26751187" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Polio endgame: the global switch from tOPV to bOPV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30157390" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ending Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/195265" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antibody persistence after primary immunization with trivalent oral poliovirus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4342327" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1200025" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4142936" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Factors affecting the efficacy of live poliovirus vaccine in warm climates. Efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4423450" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antipoliomyelitis program in Brazil; a erologic study of immunity levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6740094" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6740094" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852907" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of diarrhea on the humoral response to oral polio vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980048" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26476367" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26318714" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36162417" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36162417" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6150332" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outbreak of paralytic poliomyelitis, Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9203713" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7866703" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The 5' noncoding region and virulence of poliovirus vaccine strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15543587" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675890" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vaccine-derived poliomyelitis 12 years after infection in Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25316859" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15479934" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vaccine policy changes and epidemiology of poliomyelitis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vaccine-associated paralytic poliomyelitis among immunodeficient persons</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1151541" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Letter: Risk of live poliovirus in immunodeficient children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153180" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vaccine-derived polioviruses and the endgame strategy for global polio eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731948" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : "Endgame" issues for the global polio eradication initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731948" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : "Endgame" issues for the global polio eradication initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564574" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Congenital malformations and oral poliovirus vaccination during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039410" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Polio vaccines: WHO position paper–March, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27212429" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388534" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29126173" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29126173" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661857" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661857" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38060431" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580728" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006826" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Interim CDC guidance for polio vaccination for travel to and from countries affected by wild poliovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923176" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Monovalent oral poliovirus vaccines--a good tool but not a total solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106296" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Circulating vaccine-derived polioviruses: current state of knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1646664" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Response to immunization against polio after allogeneic marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8038308" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
